Proton Pump Inhibitors News

Related Pharmaceuticals Industry News

• July 2024: The United States Food and Drug Administration approved four whey protein hydrolysates from Arla Foods Ingredients for use in early-life nutrition. These ingredients, Peptigen and Lacprodan, are designed to aid in allergy management and promote gut comfort.
• October 2023: Arla Foods Ingredients upgraded its Porteña facility in Argentina to meet the rising global demand for high-quality whey ingredients, with a particular focus on Latin America. A key enhancement was the installation of a new drying tower, which boosted the capacity for whey permeate powder and enabled the production of infant-formula-grade proteins, such as alpha-lactalbumin.

• June 2024: Eli Lilly and Company presented positive results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, at the European Association for the Study of the Liver (EASL) Congress 2024 to evaluate the investigational use of tirzepatide in adults with biopsy-proven metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis.
• March 2024: Ionis Pharmaceuticals Inc. reported positive results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor with both doses (120 mg and 90 mg) in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

• May 2024: Sharp, a worldwide frontrunner in contract packaging, clinical supply services, and small-scale sterile manufacturing, has unveiled its intentions to expand its Macungie, Pennsylvania, facility in North America. This move aims to bolster the site's production capacity for the secondary packaging of sterile injectables. Macungie's expansion will boost its capacity for secondary packaging activities. These include vial labeling, assembly and labeling of pre-filled syringes (PFS), assembly and labeling of autoinjectors/pens, as well as kitting and cartoning of injectables, catering specifically to pharmaceutical and biotech firms.
• April 2024: Eli Lilly and Company entered into a definitive agreement with Nexus Pharmaceuticals, LLC, a prominent sterile manufacturer in the pharmaceutical sector, to acquire one of Nexus's manufacturing facilities. By acquiring this FDA-approved facility in Pleasant Prairie, Wisconsin, Lilly is set to bolster its global network for parenteral (injectable) product manufacturing, catering to the rising demand for its medicines. Lilly projects that production at this facility may commence by late 2025.

• April 2023: Jaguar Health Inc. signed an exclusive 5-year in-license agreement with the UK-based Venture Life Group PLC. This agreement was signed for Venture Life's FDA-approved oral mucositis prescription product, Gelclair, for the US market.
• April 2024: Napo Pharmaceuticals expanded its footprint to include cancer-related supportive care and recent in-licensing of the oral mucositis product Gelclair. The company planned to commercially launch FDA-approved Gelclair prescription gel for oral mucositis in Q3 2024.

• September 2024: Bioniq announced its partnership with healthcare reimbursement and HSA/FSA spending solution Truemed. This partnership signifies that Bioniq’s unique pharmaceutical-grade nutritional supplements can be medically necessary, allowing for HSA and FSA to spend on the preventative healthcare routine.
• February 2024: Riise, a Berlin-based supplement startup, introduced its personalized microgranule nutrient blends, catering to individual nutritional needs and health objectives, thus eliminating the necessity for multiple pills and capsules.

• August 2024: Ghai Homoeo Remedies (GHR) unveiled its latest healthcare innovation, the CoughElixir Syrup, in India. This new syrup underscores GHR's steadfast dedication to quality and effectiveness. Meticulously crafted, CoughElixir Syrup combines natural ingredients such as Aconite napellus, Arsenicum album, Antimonium tartaricum, Bryonia alba, Belladonna, Ipecacuanha, and Chelidonium majus. This distinctive homeopathic formulation is designed to provide targeted relief from a diverse range of cough symptoms.
• August 2023: Awshad re-launched a cannabis-based medicated elixir in India, targeting patients seeking alternative therapeutic options. This product is part of a broader trend toward natural remedies and personalized medicine within the pharmaceutical industry, reflecting a growing consumer interest in holistic health solutions.

• May 2024: Winner Medical Co. Ltd, a manufacturer of alginate dressings, wrapped up a successful exhibition at the European Wound Management Association (EWMA2024) in London. At the exhibition, Winner Medical's products garnered notable attention, particularly the Advanced Wound Dressing Experiment Interaction, which was met with high acclaim from attendees.
• February 2022: Winner Medical's silver alginate dressing secured the US Food and Drug Administration market access (510K). This approval not only paves the way for the product's entry into the US market but also signals Winner Medical's intent to further expand its business footprint in North America.

• January 2024: Samsung Biologics presented its 2024 business strategy at a conference held in the United States. At the conference, the company showed its commitment to accelerate its efforts to manufacture high-quality biomedicines to meet the evolving global demand.
• May 2023: MilliporeSigma, a business of Merck KGaA, expanded its contract, development, and manufacturing organization in the United States to bolster its manufacturing capabilities of antibody-drug conjugates and highly potent active pharmaceutical ingredients.

• August 2024: Radiopharmaceutical biotech company ITM Isotope Technologies Munich received regulatory approval to begin production of the medical radioisotope lutetium-177 at the NOVA facility in Neufahrn, near Munich, Germany.
• June 2024: SHINE Technologies began supplying Blue Earth Therapeutics with lutetium-177 chloride (llumira), a key material for a prostate cancer drug clinical trial. This partnership highlights the critical role of effective supply chain management in ensuring the availability of essential materials for radiopharmaceutical production.

• In May 2024, Teva Pharmaceutical Industries Ltd. launched SIMLANDI (adalimumab-ryvk) injection in the United States as an interchangeable biosimilar to Humira for the treatment of adult ankylosing spondylitis and other conditions.
• In December 2023, UCB secured approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for BIMZELX (bimekizumab). This approval is specifically for treating adults with psoriatic arthritis (PsA), non-radiographic axSpA (nr-axSpA), and ankylosing spondylitis (AS) who haven't adequately responded to current therapies.